BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of lung cancer, independently of smoking. However, the relationship between COPD and total cancer mortality is less certain. A study was undertaken to investigate the association between COPD and total cancer mortality and to determine whether the use of statins, which have been associated with cancer risk in other settings, modified this relationship. METHODS: The study included 3371 patients with peripheral arterial disease who underwent vascular surgery between 1990 and 2006; 1310 (39%) had COPD and the rest did not. The primary end point was cancer mortality (lung and extrapulmonary) over a median follow-up of 5 years. RESULTS: COPD was associated with an increased risk of both lung cancer mortality (hazard ratio (HR) 2.06; 95% CI 1.32 to 3.20) and extrapulmonary cancer mortality (HR 1.43; 95% CI 1.06 to 1.94). The excess risk was mostly driven by patients with moderate and severe COPD. There was a trend towards a lower risk of cancer mortality among patients with COPD who used statins compared with patients with COPD who did not use statins (HR 0.57; 95% CI 0.32 to 1.01). Interestingly, the risk of extrapulmonary cancer mortality was lower among statin users with COPD (HR 0.49; 95% CI 0.24 to 0.99). CONCLUSIONS: COPD was associated with increased lung and extrapulmonary cancer mortality in this large cohort of patients with peripheral arterial disease undergoing vascular surgery. The risk of lung cancer mortality increased with progression of COPD. Statins were associated with a reduced risk of extrapulmonary cancer mortality in patients with COPD.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of lung cancer, independently of smoking. However, the relationship between COPD and total cancer mortality is less certain. A study was undertaken to investigate the association between COPD and total cancer mortality and to determine whether the use of statins, which have been associated with cancer risk in other settings, modified this relationship. METHODS: The study included 3371 patients with peripheral arterial disease who underwent vascular surgery between 1990 and 2006; 1310 (39%) had COPD and the rest did not. The primary end point was cancer mortality (lung and extrapulmonary) over a median follow-up of 5 years. RESULTS:COPD was associated with an increased risk of both lung cancer mortality (hazard ratio (HR) 2.06; 95% CI 1.32 to 3.20) and extrapulmonary cancer mortality (HR 1.43; 95% CI 1.06 to 1.94). The excess risk was mostly driven by patients with moderate and severe COPD. There was a trend towards a lower risk of cancer mortality among patients with COPD who used statins compared with patients with COPD who did not use statins (HR 0.57; 95% CI 0.32 to 1.01). Interestingly, the risk of extrapulmonary cancer mortality was lower among statin users with COPD (HR 0.49; 95% CI 0.24 to 0.99). CONCLUSIONS:COPD was associated with increased lung and extrapulmonary cancer mortality in this large cohort of patients with peripheral arterial disease undergoing vascular surgery. The risk of lung cancer mortality increased with progression of COPD. Statins were associated with a reduced risk of extrapulmonary cancer mortality in patients with COPD.
Authors: Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami Journal: Pharmacol Ther Date: 2014-02-26 Impact factor: 12.310
Authors: Sukhwinder Singh Sohal; Amir Soltani; David Reid; Chris Ward; Karen E Wills; H Konrad Muller; Eugene Haydn Walters Journal: Int J Chron Obstruct Pulmon Dis Date: 2014-05-27
Authors: Ruyi Huang; Yongyue Wei; Rayjean J Hung; Geoffrey Liu; Li Su; Ruyang Zhang; Xuchen Zong; Zuo-Feng Zhang; Hal Morgenstern; Irene Brüske; Joachim Heinrich; Yun-Chul Hong; Jin Hee Kim; Michele Cote; Angela Wenzlaff; Ann G Schwartz; Isabelle Stucker; John Mclaughlin; Michael W Marcus; Michael P A Davies; Triantafillos Liloglou; John K Field; Keitaro Matsuo; Matt Barnett; Mark Thornquist; Gary Goodman; Yi Wang; Size Chen; Ping Yang; Eric J Duell; Angeline S Andrew; Philip Lazarus; Joshua Muscat; Penella Woll; Janet Horsman; M Dawn Teare; Anath Flugelman; Gad Rennert; Yan Zhang; Hermann Brenner; Christa Stegmaier; Erik H F M van der Heijden; Katja Aben; Lambertus Kiemeney; Juan Barros-Dios; Monica Pérez-Ríos; Alberto Ruano-Ravina; Neil E Caporaso; Pier Alberto Bertazzi; Maria Teresa Landi; Juncheng Dai; Hongbing Hongbing Shen; Guillermo Fernandez-Tardon; Marta Rodriguez-Suarez; Adonina Tardon; David C Christiani Journal: EBioMedicine Date: 2015-11 Impact factor: 8.143